This prospective, single center, non-comparative, 90-day follow-up, post-market clinical investigation of etafill in patients undergoing cataract surgery.

The performance is measured by the preservation of endothelial cells measured by specular microscopy at the follow-up visit in comparison to baseline values.

Inclusion Criteria:

• Patients indicated for cataract surgery via the anterior chamber
• A negative urine pregnancy test at Visit 1 or 2
• Capability to understand information about the investigation, including patients' obligations, and willingness to take part, as evidenced by signed and dated informed consent

Exclusion Criteria:

• Patients with a known hypersensitivity to HA or other components of the device.
• Patients with corneal scars or corneal dystrophies interfering with study measurements
• Abnormal intraocular pressure which would interfere with surgery and follow up (in opinion of the investigator)
• Any other condition that in the opinion of the investigator would interfere with the participation in this investigation
• Any person dependent on the investigator or employees of the investigation site institution or the Sponsor.
• Current or previous (within 30 days of enrollment) treatment with another investigational drug and/or medical device or participation in another clinical study
• Patients whose participation in clinical trials is prohibited by the Austrian Medical Devices Act

The study patients will be recruited by the investigator, among patients scheduled to receive a standard cataract surgery taking inclusion and exclusion criteria into account. The investigator may also offer participation in the study to potential candidates identified in their patient database.